CD4+ and CD8+ T cells cultured in CM obtained from mGSCs pre-treated with ITD-1 or from TGFBR2-knockdown GBM cells displayed enhanced TCR-independent tumor cell-killing capacity compared to T cells cultured in either unconditioned medium or in CM from control mGSCs (DMSO-treated or no doxycycline) (Figure 4D and Figure S3F). The gene discussed is TGFBR2; the disease is glioblastoma.